DexCom (NASDAQ:DXCM – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Monday.
A number of other equities analysts also recently commented on the stock. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Redburn Atlantic began coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Finally, Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.94.
DexCom Stock Up 0.7 %
Shares of DXCM stock traded up $0.78 during mid-day trading on Monday, reaching $116.57. 2,298,421 shares of the company were exchanged, compared to its average volume of 2,926,553. DexCom has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market capitalization of $46.36 billion, a P/E ratio of 75.21, a P/E/G ratio of 2.83 and a beta of 1.22. The business’s 50 day simple moving average is $129.24 and its 200 day simple moving average is $125.92.
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Research analysts predict that DexCom will post 1.78 earnings per share for the current year.
Insider Buying and Selling at DexCom
In related news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold a total of 187,293 shares of company stock valued at $25,295,452 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On DexCom
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DSM Capital Partners LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $28,000. Crewe Advisors LLC acquired a new position in shares of DexCom during the first quarter worth approximately $29,000. Valley National Advisers Inc. lifted its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Riverview Trust Co acquired a new position in shares of DexCom during the first quarter worth approximately $32,000. Finally, MV Capital Management Inc. lifted its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.